Loading data for ALMR — first visit, this takes a few seconds.

Alamar Biosciences, Inc. (ALMR)

NasdaqGS: ALMR · Real-Time Price · USD

30.71

-2.29 (-6.94%)

At close: Aug 31, 2026, 1:49 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	30.62
Market Cap	2.14B
Revenue (ttm)	100M
Net Income (ttm)	-49.7M
	0.00
	-0.72
	n/a
	-56.82
P/B (ttm)	6.84
P/S (ttm)	21.30
Earnings Date	Nov 5, 2026

Ask	39.25
Volume	267,640
Avg. Volume (20D)	324,509
Open	32.70
Previous Close	33.00
Day's Range	30.45 - 33.54
52-Week Range	18.85 - 38.54
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ALMR

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomar...

[Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Apr 17, 2026

Employees 286

Stock Exchange NasdaqGS

Ticker Symbol ALMR

Website https://alamarbio.com

Full Company Profile

Financial Performance

In 2025, Alamar Biosciences's revenue was 74.21M, an increase of 195.17% compared to the previous year's 25.14M. Earnings were -29.82M, a decrease of -36.65%.

Financial Statements

Earnings Surprise

Alamar Biosciences has released their quarterly earnings on Aug 10, 2026:

Revenue of $26.04M misses estimates by $0, with Infinity% YoY growth.
EPS of -0.2 exceeds estimates by 0.12, with -Infinity% YoY decline.

Next Earnings Release

Alamar Biosciences, Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · Motley Fool

Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript

Revenue surged 82% year-over-year to $29.4 million.

3 weeks ago · GuruFocus.com

Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ...

Record 60% gross margin and expanded ADDI partnership position the company for 59% annual growth, despite widening net losses and near-term margin fluctuations.

3 weeks ago · Simply Wall St.

Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales

Alamar Biosciences stock has gained 27.2% year to date, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. That mix of strong recent returns and a low value s...

3 weeks ago · MarketBeat

Alamar Biosciences Q2 Earnings Call Highlights

Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue su...

3 weeks ago · BioPharma Dive

Attovia adds to biotech IPO momentum with $289M offering

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

Page 1 of 2

Alamar Biosciences, Inc. (ALMR)